×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| 530019 | 602.0 | 58.0 | 595.0 | 0.26 | 17,776 | 36.6 |
| Concord Biotech Limited | 2176.65 | 425.65 | 2039.88 | 4.07 | 17144 | 48.1 |
| CAPLIN POINT LABORATORIES LTD. | 2146.0 | 858.9 | 1825.7 | 11.26 | 17032 | 30.2 |
JUBILANT PHARMOVA LIMITED, with Security Code 530019, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182.7 | 199.8 | 217.4 | 186.3 | 175.2 | 205.8 | 166.7 | 165.7 | 196.0 | 59.5 |
| Expenses | 184.6 | 197.7 | 213.2 | 185.5 | 175.9 | 193.6 | 165.5 | 171.8 | 185.0 | 49.2 |
| Operating Profit | -1.9 | 2.2 | 4.2 | 0.8 | -0.7 | 12.2 | 1.2 | -6.1 | 11.0 | 10.3 |
| OPM % | -1.03% | 1.09% | 1.93% | 0.43% | -0.4% | 5.93% | 0.72% | -3.68% | 5.61% | 17.31% |
| Other Income | 7.9 | 13.7 | 15.9 | 18.4 | 19.0 | 50.1 | 8.3 | 43.8 | 18.4 | 0.7 |
| Interest | 5.5 | 5.7 | 6.4 | 7.1 | 8.3 | 8.1 | 7.6 | 7.8 | 7.4 | 3.0 |
| Depreciation | 11.6 | 11.4 | 11.4 | 11.9 | 12.3 | 12.7 | 13.1 | 13.3 | 13.3 | 1.5 |
| Profit before tax | -11.1 | -1.2 | 2.3 | 0.2 | -2.3 | 41.5 | 0.0 | 16.6 | 8.7 | 6.5 |
| Tax % | -47.1% | 2408.9% | -17.4% | -300% | 4.3% | -21.7% | -8.9% | 36.7% | 39.1% | 36.9% |
| Net Profit | -5.9 | -30.9 | 1.9 | -0.4 | -2.4 | 32.5 | -10.2 | 10.5 | 5.3 | 5.8 |
| EPS in Rs | -0.37 | -1.94 | 0.12 | -0.03 | -0.15 | 2.05 | -0.64 | 0.66 | 0.33 | 0.36 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,552.5 | 1,678.0 | 1,586.9 | 1,680.3 | 1,677.1 | 175.9 | 1,731.7 | 1,752.3 | 1,821.7 | 1,928.8 |
| Expenses | 1,408.3 | 1,458.8 | 1,418.7 | 1,438.5 | 1,459.1 | 148.7 | 1,480.2 | 1,463.0 | 1,534.6 | 1,583.5 |
| Operating Profit | 144.2 | 219.2 | 168.2 | 241.8 | 218.0 | 27.1 | 251.5 | 289.3 | 287.1 | 345.3 |
| OPM % | 9.29% | 13.06% | 10.6% | 14.39% | 13% | 15.43% | 14.52% | 16.51% | 15.76% | 17.9% |
| Other Income | 9.5 | 4.5 | 8.6 | 9.9 | 35.8 | -15.5 | 14.0 | 7.5 | -9.7 | 8.6 |
| Interest | 50.7 | 55.6 | 61.9 | 66.1 | 71.3 | 7.3 | 71.0 | 61.0 | 55.6 | 52.7 |
| Depreciation | 94.3 | 271.2 | 89.7 | 96.6 | 94.6 | 10.1 | 90.7 | 91.4 | 91.3 | 95.2 |
| Profit before tax | 8.7 | -103.1 | 25.2 | 89.0 | 87.9 | 11.2 | 103.8 | 158.6 | 149.4 | 209.3 |
| Tax % | -238.6% | 13.7% | -72.2% | -40.3% | -39.4% | 14.2% | 3.6% | -29% | -22.8% | -26.5% |
| Net Profit | -16.0 | -100.5 | 6.0 | 62.1 | 66.4 | -6.2 | 481.8 | 102.5 | 100.7 | 151.3 |
| EPS in Rs | -0.98 | -6.15 | 0.4 | 3.94 | 4.2 | -3.68 | 30.35 | 6.46 | 6.36 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -25% |
| 3 Years: | 1% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -40% |
| 3 Years: | -33% |
| TTM: | -24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 21% |
| 3 Years: | 38% |
| 1 Year: | 49% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | -10% |
| 3 Years: | 10% |
| TTM: | 1257% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 21% |
| 3 Years: | 38% |
| 1 Year: | 49% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|